Zobrazeno 1 - 8
of 8
pro vyhledávání: '"L. Pietragallo"'
Autor:
Ahmad A. Tarhini, Mathew Sulecki, Suzanne Lentzsch, L. Pietragallo, Diana Lenzner, Patricia Kropf, Stanley M. Marks, Dhaval R. Mehta, Kenneth A. Foon, Michael Boyiadzis
Publikováno v:
Blood. 119(13)
To the editor: Chemoimmunotherapy with fludarabine (F), cyclophosphamide (C), and rituximab (R) is currently considered the gold standard first-line therapy for chronic lymphocytic leukemia (CLL).[1][1] In an attempt to reduce the neutropenia and mai
Autor:
Stanley M. Marks, Diana Lenzer, Ahmad A. Tarhini, L. Pietragallo, Anastasios Raptis, Mathew Sulecki, P.M. Schaefer, D. Meisner, Michael Boyiadzis, Stephanie R. Land, Andrew D. Laman, Kenneth A. Foon, Allyson R. Butchko
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 27(4)
Purpose Chemoimmunotherapy combining fludarabine, cyclophosphamide, and rituximab (FCR) is an active regimen for untreated patients with chronic lymphocytic leukemia (CLL) with 70% complete responses (CRs) and 95% overall responses (ORs). However, gr
Autor:
J. Franklin Viverette, Mohammad Abbas, Vida Almario Passero, John K. Waas, Ryan Kennedy, Markus Y. Mapara, Anastasios Raptis, Jennifer L. Osborn, Min Sun, Amy K. O’Sullivan, Terry Evans, Jing-Zhou Hou, Diane Gardner, G. David Roodman, Theodore L. Crandall, Suzanne Lentzsch, Daniel Petro, Robert L. Redner, Lijun Dai, Robert Volkin, Daniel P. Normolle, Carrie Andreas, L. Pietragallo, Ronald Fierro, Vincent Reyes, Yongli Shuai, Stanley M. Marks, R. A. Pinkerton
Publikováno v:
Blood. 118:4142-4142
Abstract 4142 Introduction: High dose chemotherapy combined with autologous stem cell transplantation (ASCT) as opposed to conventional chemotherapy improved progression free survival (PFS) and overall survival (OS) in multiple myeloma (MM) and is cu
Autor:
Ahmad A. Tarhini, P.M. Schaefer, M. Sulecki, D. Meisner, Stephanie R. Land, Andrew D. Laman, Stanley M. Marks, L. Pietragallo, Kenneth A. Foon
Publikováno v:
Blood. 110:2037-2037
Introduction Standard FCR therapy in untreated CLL patients (F-25 mg/m2 d1–3 q 4wk; C-250 mg/m2 d 1–3 q 4wk; R-500 mg/m2 d1 q 4wk for 6 cycles) was reported to have complete remissions (CR) of 70% and overall responses (OR) of 95% (J Clin Oncol20
Autor:
L. Pietragallo, R. A. Pinkerton, Ahmad A. Tarhini, S. Sukaly, Kenneth A. Foon, M. Sulecki, P.M. Schaefer, J. Obsorn, Stephanie R. Land, F. Lim, Gauri J. Kiefer, D. Meisner
Publikováno v:
Blood. 108:2844-2844
Introduction Standard FCR therapy in untreated CLL patients (F-25 mg/m2 d1–3 q 4wk; C-250 mg/m2 d 1–3 q 4wk; R-500 mg/m2 d1 q 4wk for 6 cycles) was recently reported to have complete remission (CR) of 70% and overall responses (OR) of 95% (J Clin
Autor:
Ahmad A. Tarhini, Kenneth A. Foon, Gauri J. Kiefer, P.M. Schaefer, R. A. Pinkerton, Felix Lim, D. Meisner, M. Sulecki, Stephanie R. Land, L. Pietragallo
Publikováno v:
Journal of Clinical Oncology. 24:6599-6599
6599 Background: Recent data reporting results of FCR therapy in previously untreated advanced CLL patients (F-25 mg/m2 d1–3 q 4wk; C-250 mg/m2 d 1–3 q 4wk; R-500 mg/m2 d1 q 4wk for 6 cycles) demonstrated complete remission (CR) of 70% and overal
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.